Company Encyclopedia
View More
name
Femasys
FEMY.US
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations.
1.358 T
FEMY.USMarket value -Rank by Market Cap -/-

Financial Score

07/11/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking131/170
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-329.45%E
    • Profit Margin-1113.68%E
    • Gross Margin61.35%A
  • Growth ScoreB
    • Revenue YoY98.61%A
    • Net Profit YoY-25.90%D
    • Total Assets YoY-32.04%E
    • Net Assets YoY-86.60%E
  • Cash ScoreB
    • Cash Flow Margin-8.98%D
    • OCF YoY98.61%A
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreE
    • Gearing Ratio89.06%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Femasys Inc expected to post a loss of 13 cents a share - Earnings Preview

    Femasys Inc is anticipated to report a quarterly revenue increase of 161.3% to $1.45 million for the period ending September 30, 2025, with a projected loss of 13 cents per share. The average analyst rating is "buy," with no holds or sells. The median 12-month price target is $6.00, representing an 82.7% upside from the last closing price of $1.04.

    Reuters·
    US
    FEMY
    +33.13%
    Reuters·
    US
    FEMY
    +33.13%

    Femasys Inc. Announces Private Placement of Convertible Notes and Warrants

    Femasys Inc. has announced a private placement of senior secured convertible notes and warrants with accredited investors. The notes are convertible into common stock at $0.73 per share, and investors will receive warrants with exercise prices of $0.81, $0.92, and $1.10. The funds will be used to repay previous notes and for corporate purposes. Company insiders participated, purchasing about $100,000 in notes and warrants. Femasys will file a registration statement for the resale of shares.

    Reuters·
    US
    FEMY
    +33.13%
    Reuters·
    US
    FEMY
    +33.13%

    Femasys Secures FDA IDE Approval to Advance Final FemBloc Trial Phase

    Femasys Inc. has received FDA Investigational Device Exemption (IDE) approval to proceed with enrollment in the final phase of the FINALE trial for its FemBloc birth control device. This approval follows the successful completion of the trial's first part and is a significant step towards obtaining U.S. Pre-Market Approval (PMA) for FemBloc. The announcement pertains solely to Femasys Inc.

    Reuters·
    US
    FEMY
    +33.13%
    Reuters·
    US
    FEMY
    +33.13%

    Femasys Meets Nasdaq Equity Requirement After Offering

    Femasys (FEMY) has met Nasdaq's equity requirement after a recent offering, reporting a pro forma stockholders’ equity of approximately $5.2 million as of October 15, 2025. Nasdaq will monitor compliance to avoid delisting. Analysts rate FEMY stock as a Hold with a $0.50 price target, while Spark's AI Analyst considers it Neutral due to financial challenges and negative valuation metrics. The current market cap is $25.86 million, with an average trading volume of 5,225,732 shares.

    Tip Ranks·
    US
    FEMY
    +33.13%
    Tip Ranks·
    US
    FEMY
    +33.13%

    Femasys Inc. Receives Nasdaq Notice for Listing Rule Noncompliance

    Femasys Inc. has received a notice from Nasdaq regarding noncompliance with listing rules due to its market value falling below the $35 million minimum. The company also did not meet alternative requirements for stockholders’ equity and net income. However, after an $8 million offering, Femasys estimates its stockholders’ equity at approximately $5.2 million as of October 15, 2025, exceeding the $2.5 million minimum. Nasdaq will monitor compliance, and delisting remains a possibility if standards are not maintained.

    Reuters·
    US
    FEMY
    +33.13%
    Reuters·
    US
    FEMY
    +33.13%